Abbott's $670M NEC Settlement Lands as the First Federal Bellwether Trial Plays Out

Abbott Laboratories announced on August 20, 2026 that it will pay approximately $670 million to resolve the Gill v. Abbott case and necrotizing enterocolitis (NEC) claims asserted on behalf of roughly 2,000 additional infants. The deal lands the same week the first federal NEC bellwether trial began against a different defendant, Mead Johnson, in Chicago.

The settlement closes out the $495 million Missouri jury verdict that a St. Louis jury returned against Abbott in 2024, a judgment the Missouri Court of Appeals affirmed in May 2026. According to Abbott's SEC filing, rather than continue appealing or pay roughly $600 million in judgment plus accrued interest, the company chose to settle Gill and the additional NEC claims for an aggregate $670 million.

Two case counts circulate in coverage of this settlement, and they measure different things. The 825 figure counts lawsuits pending in federal MDL 3026 alone, as reported by the JPML on August 3, 2026, before the settlement began removing claims. Abbott's 1,700 figure is broader: it counts every lawsuit still pending against Abbott in state and federal courts combined after the settlement, brought on behalf of roughly 12,700 infants.

The Verdict That Forced Abbott's Hand

Abbott's settlement covers only a portion of the litigation and does not include Mead Johnson, which Reckitt Benckiser Group owns. The deal resolves cases brought by three plaintiffs' firms (Chicago's TorHoerman Law, the Holland Law Firm in St. Louis, and Nashville's Stranch, Jennings & Garvey) and explicitly disclaims any admission of liability. Abbott maintains that the FDA, NIH, CDC, and the American Academy of Pediatrics recognize its preterm formula products as safe.

The economics behind the timing are specific: interest on the affirmed Gill judgment alone would have pushed Abbott's exposure on that single case to roughly $600 million. Settling Gill together with the additional 2,000-infant block, rather than litigating each claim individually, gave Abbott a fixed number instead of an open-ended appellate and trial calendar.

Inman: The Trial Abbott's Deal Doesn't Touch

While Abbott negotiated its settlement, jury selection began August 13 in Inman v. Mead Johnson & Co., Case No. 1:22-cv-03737, part of MDL No. 3026 before U.S. District Judge Rebecca R. Pallmeyer. Opening arguments followed on August 17. Plaintiff Alexis Inman alleges her son, Daniel Windley, died of NEC after being fed Mead Johnson's Enfamil Premature formula, and that Mead Johnson failed to warn her medical providers of the risk.

As of August 22, 2026, the trial remains ongoing with no reported verdict. Inman is the first of four selected bellwether cases in MDL 3026 to actually reach a jury: Judge Pallmeyer granted summary judgment to Abbott in three earlier test cases, and the Seventh Circuit upheld the first of those rulings in July 2026. A verdict in Inman won't bind the roughly 825 other cases pending in the federal MDL, but it will be the first read on how a federal jury weighs the same causation evidence that has produced split results in state courts.

The Records That Decide These Cases

Whether a claim reaches a jury or gets dismissed on summary judgment consistently comes down to documentation. NEC litigation runs on a specific evidence chain, and gaps anywhere in it are what defense motions target first.

Premature infants are frequently transferred between a birth hospital, a tertiary Level IV NICU, and later outpatient pediatric specialists, which means a single claimant's file can span three or more institutions before discharge. LlamaLab retrieves these records in 4 days on average, with roughly 30-40% returned same-day on portal and electronic requests, and its reverse provider search uses insurance data to surface treatment locations families don't always remember. Each file comes with an itemized per-case invoice that flows through as a recoverable case disbursement on settlement statements.

What Firms Should Do Now

The Bottom Line

Abbott's settlement removes one defendant's largest verdict from the docket, but it leaves the underlying question unresolved: how a jury weighs NEC causation evidence when the case actually reaches trial. Inman is answering that question in real time, and the outcome will matter far beyond the Mead Johnson cases it directly touches.

For firms with pending claims against either manufacturer, the immediate task hasn't changed. Complete NICU, feeding, and pathology files are what separated the plaintiffs who won at trial from the ones dismissed on summary judgment, and that will remain true whichever way Inman ends.

Sources: Abbott press release, Aug. 20, 2026, Abbott 8-K filing (SEC EDGAR), Law.com, Levin Law, Law.com (preemption ruling), Top Class Actions, MDL Update (JPML Aug. 3, 2026 statistics), Med Legal Pro. This article is for informational purposes only and does not constitute legal or medical advice.